文献速递头颈与中枢神经肿瘤

免疫治疗时代基于第九版AJCC/UICC TNM分期系统对鼻咽癌M1分期的验证与改进:一项多中心队列研究

Validation and development of a refined M1 category for nasopharyngeal carcinoma based on the version-nine of AJCC/UICC TNM staging system in the immunotherapy era: A multicenter cohort study.
PubMed 文献 · Eur J Cancer · 2025-02-12

该多中心队列研究纳入2019年1月至2023年6月接受姑息化疗和免疫检查点抑制剂的472例M1鼻咽癌患者,按TNM-9重新分期并分析生存。中位随访27个月,M1a亚组2年总生存率和无进展生存率均显著高于M1b亚组。研究基于RPA模型提出新的RPA-M1分期,较TNM-9的M1分期对生存结局的区分更精细。

要点

  • TNM-9的M1分期在免疫治疗时代仍适用,M1a与M1b亚组生存差异显著。
  • 新RPA-M1分期将患者分为RPA-M1a、RPA-M1b和RPA-M1c三组,2年OS率分别为91.5%、81.4%和69.8%。
  • RPA-M1分期的AIC更低、C-index更高,对生存结局的区分优于TNM-9的M1分期。

核心结论

  • TNM-9的M1分期在免疫治疗时代仍适用,RPA-M1分期较TNM-9能更精细地区分患者生存结局并支持个体化决策。

研究设计与样本

  • 多中心队列研究,纳入2019年1月至2023年6月五家中心接受姑息化疗和免疫检查点抑制剂的472例M1鼻咽癌患者,按TNM-9重新分期。

主要发现

  • 中位随访27个月,M1a亚组2年OS为90.4% vs M1b亚组73.7%(P<0.001),2年PFS为69.2% vs 40.6%(P<0.001),多因素分析进一步证实。
  • 转移器官数目是另一独立预测因素。
  • 新RPA-M1a(≤3个转移灶且限于单个器官)、RPA-M1b(≤3个转移灶但累及多个器官或>3个转移灶但限于单个器官)、RPA-M1c(>3个转移灶且累及多个器官)的2年OS率分别为91.5%、81.4%、69.8%(P<0.05),2年PFS率分别为72.4%、54.3%、29.1%(P<0.005)。
  • 与TNM-9的M1分期相比,RPA-M1分期的AIC更低,OS和PFS的C-index更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the applicability of the M1 category of the version-nine of AJCC/UICC TNM staging system (TNM-9) for M1 nasopharyngeal carcinoma (M1-NPC) in immunotherapy era and propose potential refinements. METHODS: M1-NPC patients who underwent palliative chemotherapy and immune checkpoint inhibitors (ICIs) between January 2019 and June 2023 across five institutions were included and re-staged according to TNM-9. Overall survival (OS) and Progression-free survival (PFS) were analyzed. A recursive partitioning analysis (RPA) model was employed to derive a new RPA-M1 category. RESULTS: Among the 472 patients included, 219 were M1a and 253 were M1b. With a median follow-up time of 27 months, the M1a subgroup exhibited significantly higher 2-year OS (90.4 % vs. 73.7 %) and PFS (69.2 % vs. 40.6 %) than M1b subgroup (all P<0.001), which was further confirmed by multivariate analysis (MVA). Additionally, number of involved organs was found to be another independent predictor. New RPA-M1 category were then developed: RPA-M1a (≤3 metastatic lesions and confined to one single organ), RPA-M1b (≤3 metastatic lesions but involving multiple organs or >3 lesions and confined to one single organ), and RPA-M1c (patients with >3 metastatic lesions and involving multiple organs), with 2-year OS rates of 91.5 %, 81.4 %, and 69.8 %, respectively (P < 0.05) and PFS rates of 72.4 %, 54.3 % and 29.1 %, respectively (P < 0.005). Compared to the M1 Category in TNM-9, RPA-M1 category had a lower Akaike Information Criterion (AIC) and a higher concordance index (C-index) for OS and PFS. CONCLUSION: The M1 category in the TNM-9 is applicable in the immunotherapy era. The RPA-M1 category offers improve depiction of survival outcomes compared to TNM-9, allowing for more refined stratification of patient outcomes and individulized decision-tailoring.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Xu H, Hu Y, Xie T, et al. Validation and development of a refined M1 category for nasopharyngeal carcinoma based on the version-nine of AJCC/UICC TNM staging system in the immunotherapy era: A multicenter cohort study. Eur J Cancer. 2025. PMID: 39954311. doi:10.1016/j.ejca.2025.115305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。